CN110494142A - 癌症治疗 - Google Patents

癌症治疗 Download PDF

Info

Publication number
CN110494142A
CN110494142A CN201880019933.1A CN201880019933A CN110494142A CN 110494142 A CN110494142 A CN 110494142A CN 201880019933 A CN201880019933 A CN 201880019933A CN 110494142 A CN110494142 A CN 110494142A
Authority
CN
China
Prior art keywords
inhibitors
methyl
inhibitor
daily dose
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880019933.1A
Other languages
English (en)
Chinese (zh)
Inventor
P·F·戴维斯
T·一廷唐
R·W·麻石
S·T·谈
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gillies Mcindoe Research Institute
Original Assignee
Gillies Mcindoe Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gillies Mcindoe Research Institute filed Critical Gillies Mcindoe Research Institute
Publication of CN110494142A publication Critical patent/CN110494142A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880019933.1A 2017-01-31 2018-01-31 癌症治疗 Pending CN110494142A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762452479P 2017-01-31 2017-01-31
US62/452,479 2017-01-31
PCT/NZ2018/050006 WO2018143826A1 (en) 2017-01-31 2018-01-31 Cancer therapeutic

Publications (1)

Publication Number Publication Date
CN110494142A true CN110494142A (zh) 2019-11-22

Family

ID=63040946

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880019933.1A Pending CN110494142A (zh) 2017-01-31 2018-01-31 癌症治疗

Country Status (7)

Country Link
US (2) US20200197335A1 (enExample)
EP (1) EP3576746A4 (enExample)
JP (2) JP2020515523A (enExample)
CN (1) CN110494142A (enExample)
AU (2) AU2018215857A1 (enExample)
CA (1) CA3051840A1 (enExample)
WO (1) WO2018143826A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113069443A (zh) * 2021-04-12 2021-07-06 四川大学 奈必洛尔在制备预防和/或治疗口腔白斑及口腔鳞状细胞癌的药物中的用途
CN115843246A (zh) * 2020-01-29 2023-03-24 吉利斯麦金德研究院 用于治疗血管瘤的方法和组合物
CN116963724A (zh) * 2021-03-03 2023-10-27 萨恩帕斯药物有限公司 用于人类恶性胸腔积液的治疗

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020027665A1 (en) * 2018-07-30 2020-02-06 Gillies Mcindoe Research Institute Novel pharmaceutical compositions for cancer therapy
WO2020135920A1 (en) * 2018-12-28 2020-07-02 Université Libre de Bruxelles Kit for inhaled chemotherapy, and treatment of lung cancer with said kit

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077394A1 (en) * 2004-02-11 2005-08-25 Ramot At Tel-Aviv University Ltd Compositions for treatment of cancer and inflammation with curcumin and at least one nsaid
WO2016004218A1 (en) * 2014-07-01 2016-01-07 Vicus Therapeutics, Llc Combination drug therapies for cancer and methods of making and using them
WO2016024870A1 (en) * 2014-08-12 2016-02-18 Gillies Mcindoe Research Institute Cancer diagnosis and therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016054511A1 (en) * 2014-10-02 2016-04-07 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors for prevention of aging-associated dysfunction of stem cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077394A1 (en) * 2004-02-11 2005-08-25 Ramot At Tel-Aviv University Ltd Compositions for treatment of cancer and inflammation with curcumin and at least one nsaid
WO2016004218A1 (en) * 2014-07-01 2016-01-07 Vicus Therapeutics, Llc Combination drug therapies for cancer and methods of making and using them
WO2016024870A1 (en) * 2014-08-12 2016-02-18 Gillies Mcindoe Research Institute Cancer diagnosis and therapy

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
SAHDEO PRASAD等: "Recent Developments in Delivery, Bioavailability, Absorption and Metabolism of Curcumin: the Golden Pigment from Golden Spice", 《CANCER RESEARCH AND TREATMENT》, vol. 46, no. 1, pages 2 - 18, XP055427457, DOI: 10.4143/crt.2014.46.1.2 *
SAHDEO PRASAD等: "Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spiceRecent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice", 《CANCER RESEARCH AND TREATMENT》 *
SAHDEO PRASAD等: "Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spiceRecent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice", 《CANCER RESEARCH AND TREATMENT》, vol. 46, no. 1, 31 December 2014 (2014-12-31), pages 2 - 18, XP055427457, DOI: 10.4143/crt.2014.46.1.2 *
V. C. MIRANDA等: "Exploring the role of metformin in anticancer treatments: a systematic review", 《DRUGS OF TODAY》 *
V. C. MIRANDA等: "Exploring the role of metformin in anticancer treatments: a systematic review", 《DRUGS OF TODAY》, vol. 50, no. 9, 31 December 2014 (2014-12-31), pages 623, XP055719061, DOI: 10.1358/dot.2014.50.9.2229920 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115843246A (zh) * 2020-01-29 2023-03-24 吉利斯麦金德研究院 用于治疗血管瘤的方法和组合物
CN115843246B (zh) * 2020-01-29 2026-01-06 吉利斯麦金德研究院 用于治疗血管瘤的方法和组合物
CN116963724A (zh) * 2021-03-03 2023-10-27 萨恩帕斯药物有限公司 用于人类恶性胸腔积液的治疗
CN113069443A (zh) * 2021-04-12 2021-07-06 四川大学 奈必洛尔在制备预防和/或治疗口腔白斑及口腔鳞状细胞癌的药物中的用途

Also Published As

Publication number Publication date
EP3576746A1 (en) 2019-12-11
JP2020515523A (ja) 2020-05-28
EP3576746A4 (en) 2020-09-09
WO2018143826A1 (en) 2018-08-09
JP2023075272A (ja) 2023-05-30
US20230364037A1 (en) 2023-11-16
CA3051840A1 (en) 2018-08-09
AU2024200098A1 (en) 2024-01-25
US20200197335A1 (en) 2020-06-25
AU2018215857A1 (en) 2019-08-15

Similar Documents

Publication Publication Date Title
US20230364037A1 (en) Cancer therapeutic
CN104519887B (zh) 包含B‑Raf抑制剂、EGFR抑制剂和任选PI3Kα抑制剂的药物组合
RU2737496C2 (ru) Способы лечения рака
JP6087836B2 (ja) 併用療法
CA2890663A1 (en) Pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases
JP2023145689A (ja) Ｈｅｒ２陽性がんの処置
CN119486713A (zh) 尼罗加司他治疗
KR20240104138A (ko) 니로가세스타트를 사용한 조성물 및 치료
KR20230159510A (ko) Ddr 유전자 돌연변이된 전이성 거세-감수성 전립선암의 치료를 위한 탈라조파립과 항안드로겐의 조합
US20250090514A1 (en) Method of treating cancer
CN105008394A (zh) 治疗结肠直肠癌的方法
WO2024127140A1 (en) Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer
WO2020027665A1 (en) Novel pharmaceutical compositions for cancer therapy
NZ796238A (en) Cancer therapeutic
TW202029961A (zh) Ar拮抗劑聯合parp抑制劑在製備治療前列腺癌的藥物中的用途
HK40111558A (en) Pharmaceutical composition including phthalazinone derivative for co-administration with anticancer drug
WO2026092748A1 (zh) 雄性激素合成抑制剂与parp抑制剂联合用于治疗前列腺癌
HK40121823A (en) Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer
HK40098285A (en) Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer
EA049014B1 (ru) Способ лечения рака
BR112015002384B1 (pt) Combinações farmacêuticas compreendendo um inibidor de b-raf e um inibidor de egfr, e seus usos

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20191122

WD01 Invention patent application deemed withdrawn after publication